Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: psoriasis

Join Us Virtually for the 2018 Annual Meeting with ACR Beyond Live!

  |  

Join us virtually in Chicago, as we stream the 2018 ACR Review Course and ACR/ARHP Annual Meeting live. Registration is now open, and the events will take place Oct. 20‒24. Watch the sessions live in real time, chat with other attendees, and participate in question-and-answer sessions when available. You can also enjoy access to the…

Psoriatic Arthritis Research Continues Hunt for Biomarkers

  |  

AMSTERDAM—Molecular signatures in synovial tissue that can be gathered through biopsies are a largely untapped resource that could help guide treatment for rheumatic conditions, an expert said at the EULAR: Annual European Congress of Rheumatology. “I’m convinced that looking into synovial tissue provides us with tools to not only understand mechanisms of disease in rheumatoid…

Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

  |  

AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…

Adalimumab Appears Safe for Treating Pediatric Patients with Autoimmune Disease

Reuters Staff  |  

NEW YORK (Reuters Health)—Adalimumab appears to be safe for treating pediatric patients with polyarticular juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), psoriasis and Crohn’s disease (CD), according to data from company-sponsored clinical trials. Adalimumab is an anti-tumor necrosis factor monoclonal antibody with demonstrated efficacy in these conditions, but pediatric safety data remains limited. Dr. Gerd…

EU Grants Marketing Authorization for Hyrimoz; Plus FDA Rejects New Drug Application for Buprenorphine Sublingual Spray

  |  

In late July, the European Commission granted marketing approval for Hyrimoz, which is biosimilar to adalimumab…

The Pros & Cons of Combining Different Specialties Under One Roof

Gregory C. Gardner, MD, FACP  |  

Many rheumatology patients have complex conditions and require the added expertise of colleagues in other fields, such as pulmonology, neurology or dermatology. This is even more true when patients with complex care issues are referred to academic medical centers. At such centers, patients often travel hours for an appointment and see more than one provider….

ACR & NPF Highlight Medicare Access Challenges in Capitol Hill Briefing

  |  

Concerns about how the Trump administration’s ideas to lower drug prices could reduce patient access to medicines led the ACR to speak out on many different fronts. On June 25, at a briefing hosted by the ACR and the National Psoriasis Foundation (NPF), a packed room of Congressional staffers and reporters learned from rheumatologists and…

Researchers Seek to Predict & Prevent Rheumatoid Arthritis

Jeffrey A. Sparks, MD, MMSc, & Kevin D. Deane, MD, PhD  |  

Preventing adverse outcomes in individuals who have rheumatic diseases is a daily goal for rheumatologists. For example, rheumatologists prescribe medications and perform screening to prevent erosions in rheumatoid arthritis (RA), renal failure in systemic lupus erythematosus and flares across all diseases. Many of these actions are classified as secondary or tertiary prevention, because individuals have…

Gap in Regulating Biotech Drug Copies Prompts WHO to Step In

Ben Hirschler  |  

LONDON (Reuters)—Cut-price copies of expensive biotech drugs promise to slash the cost of treating serious diseases, including cancer, in rich and poor countries alike -but uneven regulation has created a lopsided market. Now the World Health Organization (WHO) is stepping in to assess the quality of such so-called biosimilars, offering a global stamp of approval…

Novartis Receives EU Approval for Infliximab Biosimilar Zessly

Reuters Staff  |  

ZURICH (Reuters)—Novartis said its Sandoz division received approval from the European Commission for its biosimilar Zessly (infliximab) in gastroenterological, rheumatological and dermatological diseases. Zessly is approved for use in all indications of the reference medicine including rheumatoid arthritis, adult and pediatric Crohn’s disease, adult and pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis,…